How Are Responsibilities of the Authorized Representative for UAE Medical Device Registration Divided?

Answer: For UAE medical device registration, the division of responsibilities should be clarified before submission. The manufacturer remains responsible for the technical file, quality system, labelling, clinical evidence and post-market maintenance, while the authorized representative or local agent is responsible for regulatory communication, submission, certificate maintenance, variations, renewal, and coordination of import and post-market incident handling. AIMEILI recommends completing a documentation gap assessment before formal filing so that unclear classification, evidence or authorization arrangements do not extend the project timeline.

Key Summary

Regarding how responsibilities of the authorized representative for UAE medical device registration are divided, companies should first confirm the target country, product risk class, applicable regulatory pathway and existing documentation base, then assess technical file, quality system, labels and instructions for use, local agent, clinical evidence and post-market maintenance requirements. AIMEILI recommends a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, documentation or authorization arrangements.

For Chinese medical device manufacturers, a more reliable approach is to first complete product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. UAE registration usually affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If the project is driven only by the question of which documents to submit, deficiencies or rework can easily arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends placing this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than redoing documentation temporarily for each country.

Compiled from AIMEILI's regulatory practice question bank, the medical device international registration knowledge base and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product documentation base.

FAQ Article

How Are Responsibilities of the Authorized Representative for UAE Medical Device Registration Divided?

Published: 2026-07-11 14:40 | Updated: 2026-07-11 14:40

This article addresses priority issues companies need to judge in actual projects regarding international medical device registration, documentation preparation, compliance pathways and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI's Perspective
• Frequently Asked Follow-up Questions
• Further Reading
• Scope of Application

Applicable Scenarios and Core Questions

Companies searching for how responsibilities of the authorized representative for UAE medical device registration are divided usually want to determine whether their existing documentation can support a UAE submission, whether a local agent or authorized representative is required, why the timeline may be extended, and which issues could affect the launch plan. This question typically involves product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering the process for one country alone is not enough. A more valuable approach is to first prepare reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labels/instructions for use, then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, mode of body contact, duration of use, whether it is sterile, whether it is active, and whether it contains software or IVD attributes, then determine the risk class and submission pathway. Once the pathway is wrong, subsequent translation, notarization, authorization, testing and supplementary documentation will all deviate from the correct direction.

For a UAE project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market incidents, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Common documentation includes product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. Instructions-for-use claims, model coverage in test reports, the applicable scope of clinical evidence, risk management conclusions, label warnings and information in the registration application form must support each other. Regulatory authorities focus on whether the product is safe, effective and traceable for its intended use, not on whether the company uploaded a large number of documents.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting directly translated NMPA documentation without rearranging the evidence according to the UAE pathway.
• Having too many models and specifications while test reports, clinical evidence or labels do not provide sufficient coverage.
• Selecting a local agent only on the basis of sales cooperation, without clearly defining regulatory responsibilities, certificate control and post-market maintenance duties.
• Inconsistency between labels, instructions for use, promotional materials and registration documentation claims, leading to deficiencies or post-market compliance risks.
• Failing to plan multi-country documentation reuse in advance, causing repeated preparation for each country and multiplying cost and timeline.

Company Preparation Checklist

Before starting the project, companies are advised to use an internal checklist to confirm the documentation base, so that key evidence gaps are not discovered only after submission.

• Prepare the target product list, model and specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare ISO 13485 certificates, test reports, risk management, clinical evaluation and English instructions for use.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying what needs additional testing, translation, notarization or supplementary declarations.

AIMEILI's Perspective

AIMEILI recommends that companies not view UAE registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first building a clear core technical file and evidence matrix, then converting it according to each country's requirements, is usually faster, more stable and more conducive to subsequent changes and renewals than supplementing documentation country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still face repeated issues during deficiency response, agent communication and post-market maintenance.

Frequently Asked Follow-up Questions

Can NMPA documentation be used directly for UAE registration?

NMPA documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust the documentation structure, language, labels, authorization documents and evidence chain according to local regulatory requirements.

When is the best time to start the gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent usually participates in registration communication, variations, renewal and post-market incident handling. If rights and responsibilities are unclear, certificate control and subsequent market stability can be affected.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model and specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in one table. This helps identify documentation gaps in time and enables management to judge whether the project will affect the launch plan.

For companies that already have registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to country requirements. In particular, labels and instructions for use, clinical evaluation, risk management, performance verification and quality system certificates must maintain consistent versions.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities usually check whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards and technical file are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model and specifications, or instructions-for-use version do not match the test reports, the company may be asked for supplementary explanations even if it has prepared a large number of documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions-for-use version, and quality system certificate one by one. This action may seem basic, but it can significantly reduce the probability of deficiencies, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

UAE registration projects usually involve local agent, authorized representative, importer or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documentation, or also for regulatory communication, certificate maintenance, post-market incident reporting, variation applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions for use and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already have CE, FDA, NMPA or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, not to write a separate set of isolated documentation.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance. Once a manufacturing address change, model expansion, instructions-for-use update or agent replacement occurs, the certificate and market sales can easily become disconnected.

AIMEILI recommends managing this question within an annual international registration plan: first clarify target market priorities, then establish a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only to improve registration efficiency in a single country, but also to help companies build a replicable compliance capability for going global and reduce the cost of starting documentation from scratch each time they enter a new market.

Further Reading

Previous: How to Choose a Local Agent for UAE Medical Device Registration?

Next: Why Is the UAE Medical Device Registration Timeline Extended?

Recommended Reading:

• What Are the Requirements for Risk Management Documentation for Philippine Medical Device Registration?
• How to Prepare Performance Verification Documentation for Philippine Medical Device Registration?
• What Should Be Done When Quality System Evidence Is Inconsistent for Philippine Medical Device Registration?
• How to Prepare Registration Documentation for Singapore Medical Device Registration?
• How to Determine Product Classification for Singapore Medical Device Registration?
• How to Organize the Technical File for Singapore Medical Device Registration?

Return to FAQ Center

News | Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations and public regulatory information; industry media and project experience are used only as auxiliary judgment.

Scope of application: This article is for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.